GlassScriptPhysician profile
James M Galloway
NPI 1205898426
$6,215.01
in general payments reported to CMS, 2019-2025
35 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $677 · 2021: $1,331 · 2022: $1,205 · 2023: $988 · 2024: $643 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $933.84 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $655.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $528.27 | 2019-2025 | |
| Glaxosmithkline, LLC. | $523.89 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $506.80 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $369.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $345.19 | 2019-2025 | |
| Abbvie INC. | $306.81 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.21 | 2019-2025 | Jardiance |
| Abbott Laboratories | $188.33 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Merck Sharp & Dohme LLC | $186.87 | 2019-2023 | Verquvo, Belsomra, Steglujan |
| Novartis Pharmaceuticals Corporation | $163.94 | 2021-2025 | |
| Esperion Therapeutics, INC. | $131.81 | 2020-2021 | |
| Eisai INC. | $123.06 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $118.51 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $103.37 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $101.43 | 2019-2022 | |
| Biogen, INC. | $90.76 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $85.62 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.89 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $75.92 | 2020-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $55.86 | 2022-2023 | Glassia |
| Phathom Pharmaceuticals, INC. | $51.21 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $49.45 | 2019-2022 | |
| Genentech USA, INC. | $44.06 | 2021-2022 | |
| Exact Sciences Corporation | $30.71 | 2023-2025 | Cologuard Collection Kit |
| Eyevance Pharmaceuticals LLC | $30.61 | 2021 | |
| Kyowa Kirin, INC. | $21.43 | 2023 | Crysvita |
| Lundbeck LLC | $21.29 | 2023 | Rexulti |
| Boston Scientific Corporation | $19.15 | 2022 | |
| Dexcom, INC. | $14.81 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $13.83 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.73 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $12.82 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $12.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Galloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.